Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zekri

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 3, 2008
Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual functionJ M Zekri, L M El-Helw, O P Purohit, et al.
British Journal of Cancer|June 5, 2003
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphomaJ M Zekri, R E Hough, J M Davies, et al.
Pakistan Journal of Biological Sciences : PJBS|May 3, 2014
The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's diseaseM I Khairallah, L A Kassem, N A Yassin, et al.
Brain Research Bulletin|January 24, 2016
Activation of migration of endogenous stem cells by erythropoietin as potential rescue for neurodegenerative diseasesM I Khairallah, L A Kassem, N A Yassin, et al.
La Revue De Medecine Interne|January 18, 2016
[Up-to-date on the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets)]F Medhioub Kaaniche, A Chaari, O Turki, et al.
Ecancermedicalscience|January 26, 2012
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcomeJ M Zekri, E Ibrahim, B Ben Sadiq, et al.
Medical Oncology (Northwood, London, England)|November 27, 2008
Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markersEzzeldin Ibrahim, Aboelkhair M Al-Gahmi, Ahmed A Zeenelin, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi ArabiaEzzeldin M Ibrahim, Tawfik R Elkhodary, Jamal M Zekri, et al.
The Gulf Journal of Oncology|February 19, 2010
A matched case-control study of Triple negative vs. HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high risk features and poor outcomeJ M Zekri, E Ibrahim, A M Al-Gahmi, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 3, 2008
Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual functionJ M Zekri, L M El-Helw, O P Purohit, et al.
British Journal of Cancer|June 5, 2003
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphomaJ M Zekri, R E Hough, J M Davies, et al.
Pakistan Journal of Biological Sciences : PJBS|May 3, 2014
The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's diseaseM I Khairallah, L A Kassem, N A Yassin, et al.
Brain Research Bulletin|January 24, 2016
Activation of migration of endogenous stem cells by erythropoietin as potential rescue for neurodegenerative diseasesM I Khairallah, L A Kassem, N A Yassin, et al.
La Revue De Medecine Interne|January 18, 2016
[Up-to-date on the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets)]F Medhioub Kaaniche, A Chaari, O Turki, et al.
Ecancermedicalscience|January 26, 2012
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcomeJ M Zekri, E Ibrahim, B Ben Sadiq, et al.
Medical Oncology (Northwood, London, England)|November 27, 2008
Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markersEzzeldin Ibrahim, Aboelkhair M Al-Gahmi, Ahmed A Zeenelin, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi ArabiaEzzeldin M Ibrahim, Tawfik R Elkhodary, Jamal M Zekri, et al.
The Gulf Journal of Oncology|February 19, 2010
A matched case-control study of Triple negative vs. HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high risk features and poor outcomeJ M Zekri, E Ibrahim, A M Al-Gahmi, et al.
Pageof 2